21st Nov 2022 14:38
EDX Medical Group PLC - London-based developer of diagnostics products to help predict disease risk - Announces European cancer biomarker programme collaboration with Tianjin Bioscience Diagnostics Technology Co Ltd. The programme aims to improve access to reliable and cost-effective tests for cancers in the UK and Europe. EDX Medical will "conduct validation studies and submit data on individual tests to UK and EU Authorities for regulatory approval," it says. Tianjin Bioscience installed two automated digital chemiluminescence immunoassay instruments at EDX's laboratory in Cambridge. The instruments have a capacity to process up to 250,000 tests per year. Read More
